The effects of empagliflozin in patients with chronic kidney disease who are at risk for disease progression are not well understood. The EMPA-KIDNEY trial was designed to assess the effects of ...

In this double-blind trial, we randomly assigned 5988 patients with class II–IV heart failure and an ejection fraction of more than 40% to receive empagliflozin (10 mg once daily) or placebo ...

Anticipated results of the EMPEROR-Preserved trial demonstrate that the SGLT2 inhibitor empagliflozin improved clinical outcomes in patients with HF with preserved ejection fraction — the first ...

The approval is based on results from the breakthrough EMPEROR-Preserved ® Phase III trial, which investigated the effect of empagliflozin 10 mg compared with placebo once daily, both added to ...

SAN DIEGO — The significant kidney and cardiovascular benefits people with chronic kidney disease (CKD) show over 2 years of treatment with empagliflozin begin to subside within about a year ...

Empagliflozin (Jardiance) reduced the risks of chronic kidney disease (CKD) progression and cardiovascular-related deaths in high-risk patients compared with placebo, the phase III EMPA-KIDNEY ...

LEGEND achieved its primary efficacy endpoint by significantly lowering HbA1c level in both the lanifibranor arm and in the lanifibranor with empagliflozin arm compared to placebo. 50% percent of ...

Credit: Getty Images. The approval of empagliflozin for pediatric T2DM was based on data from the phase 3 DINAMO trial. Empagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor.

Empagliflozin users had 741 events compared to 712 in the DPP4i group, corresponding to a non-significant HR of 1.04. For DR progression, empagliflozin users experienced fewer events (158) than ...

kidney In addition, the companies are conducting other mechanistic studies that will evaluate the potential mechanisms by which empagliflozin may affect renal outcomes in patients with CKD.